Ignite Creation Date:
2024-05-06 @ 3:27 PM
Last Modification Date:
2024-10-26 @ 1:49 PM
Study NCT ID:
NCT04635735
Status:
TERMINATED
Last Update Posted:
2023-03-23
First Post:
2020-11-13
Brief Title:
Study of Ipilimumab After Stem Cell Transplantation in People With RelapsedRefractory Multiple Myeloma
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
A Phase III Trial of Ipilimumab After CD34-Selected Allogeneic Stem Cell Transplantation for Patients With RelapsedRefractory Multiple Myeloma
Status:
TERMINATED
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Lack of accrual
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will test the safety of ipilimumab to see what effects if any the drug has when used as maintenance therapy for people with relapsedrefractory multiple myeloma who have received chemotherapy and allogeneic hematopoietic stem cell transplant AHCT The investigators also want to find out whether giving ipilimumab after chemotherapy and AHCT is a better way to control the multiple myeloma than chemotherapy and AHCT alone
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None